CytomX Therapeutics (CTMX) Other Working Capital Changes (2018 - 2026)

CytomX Therapeutics (CTMX) has 9 years of Other Working Capital Changes data on file, last reported at -$9.6 million in Q1 2026.

• Quarterly Other Working Capital Changes rose 78.46% year-over-year to -$9.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$30.6 million (up 77.16% YoY) and the FY2025 annual result came in at -$65.6 million, up 44.53% from the prior year.
• Other Working Capital Changes fell to -$9.6 million in Q1 2026, from $551000.0 in the prior quarter.
• In the past five years, Other Working Capital Changes ranged from a high of $3.2 million in Q4 2022 to a low of -$1.6 million in Q2 2023.
• A 5-year average of $86000.0 and a median of -$1000.0 in 2022 frame the typical range for Other Working Capital Changes.
• Annual changes were most pronounced in 2022 — Other Working Capital Changes jumped 543.47% — and 2023, when it sank 159.63%.
• Tracing CTMX's Other Working Capital Changes over 5 years: stood at $45.9 million in 2022, then tumbled by 153.07% to -$24.3 million in 2023, then sank by 46.07% to -$35.6 million in 2024, then jumped by 101.55% to $551000.0 in 2025, then plunged by 1844.46% to -$9.6 million in 2026.
• The last three Other Working Capital Changes figures came in at -$9.6 million (Q1 2026), $551000.0 (Q4 2025), and -$4.4 million (Q3 2025), per Business Quant data.